Anti-inhibitor coagulant complex
- Generic Name
- Anti-inhibitor coagulant complex
- Brand Names
- Feiba
- Drug Type
- Biotech
- Unique Ingredient Identifier
- CS849DUN3M
- Background
Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.
- Indication
For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors. It is not indicated in the absence of factor VIII or IX inhibitors.
- Associated Conditions
- Bleeding caused by Hemophilia A, Bleeding caused by Hemophilia B, Perioperative bleeding caused by Hemophilia A, Perioperative bleeding caused by Hemophilia B
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Drug: Von Willebrand Factor ConcentratesDrug: Von Willebrand Factor Concentrates and Factor VIII ConcentratesDrug: Factor VIII ConcentratesDrug: Recombinant Activated Factor VII
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06883240
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇮🇹Universita' Degli Studi La Sapienza-Ist.Di Ematologia, Roma, Lazio, Italy
🇮🇹AOU Careggi, Firenze, Toscana, Italy
FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT05020483
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT04563520
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
- Conditions
- Hemophilia A With Inhibitor
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 20
- Registration Number
- NCT04205175
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
FEIBA and Use of Blood Products in Cardiac Surgery
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 12
- Registration Number
- NCT02577614
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
- Conditions
- Congenital Bleeding DisorderHaemophilia B With InhibitorsHaemophilia A With Inhibitors
- Interventions
- Drug: activated recombinant human factor VII
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 52
- Registration Number
- NCT00710619
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
The FEIBA NovoSeven Comparative Study
- Conditions
- Severe Hemophilia A With an Inhibitor
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-04-19
- Lead Sponsor
- Skane University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00166309
- Locations
- 🇸🇪
Malmo University Hospital, Malmo, Sweden
Trial of NovoSeven® in Haemophilia - Joint Bleeds
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00108797
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.